CCM
FOMX

Cadian Capital Management’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Cadian Capital Management’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-267,236
Closed -$2.17M – 105
2015
Q4 		$2.17M Hold
267,236
– – 0.08% 89
2015
Q3 		$1.96M Buy
+267,236
New +$2.72M 0.07% 78

Other funds holding FOMX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Cadian Capital Management's FOMX Position: Q1 2016 in Review

Cadian Capital Management sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2016, closing a stake of 267,236 shares — an estimated $2.17M sold.

Cadian Capital Management first reported a position in FOMX in Q3 2015 and held it in 2 quarters. The position peaked at $2.17M in Q4 2015. 66 funds tracked by Wall St. Rank hold FOMX as of Q1 2016.

  • Cadian Capital Management reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2016 after selling out during the quarter.
  • Cadian Capital Management sold 267,236 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2016, an estimated $2.17M.
  • Cadian Capital Management first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q3 2015 and held it in 2 quarters.
  • Cadian Capital Management's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $2.17M in Q4 2015.
  • 66 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2016.

Based on Cadian Capital Management's 13F filing for Q1 2016, filed 13 May 2016.